*To the Editor:* We have read with great interest the article by Marzano et al[@bib1] considering varicella-like papulovesicular exanthem as a rare but specific coronavirus disease 2019 (COVID-19)--associated skin manifestation. They included patients with a COVID-19--positive nasopharyngeal swab and no medications in the previous 15 days with varicella-like lesions.[@bib1] A previous case report of COVID19-related varicella-like vesicles had also been published by Recalcati[@bib2] for the very first time. However, only the Marzano et al[@bib1] article included scarce clinical images due to safety or logistic concerns.

In these past few weeks we have been living in an epidemic situation in Spain, considered by the World Health Organization as an area of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) of community transmission, especially in Madrid.[@bib3] Since then, we began to observe different skin manifestations in patients with COVID-19 infection. We encountered 3 in-ward patients during the last few weeks, all with microbiologically proven COVID-19 by nasopharyngeal swab, and all of them presenting with vesicles ([Table I](#tbl1){ref-type="table"}, [Figs 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"} ).Table ISummary of patients with coronavirus disease 2019 (*COVID-19*) positivity and cutaneous scattered vesiclesPatientSexAge, yPast relevant medical historyCOVID symptomsChest x-rayTotal number of days since onset of symptomsMedicationsLymphocyte count[∗](#tbl1fnlowast){ref-type="table-fn"}1Female59NoneFever\
Dry cough\
DyspneaBilateral interstitial pneumonia25Hydroxychloroquine\
Lopinavir/ritonavir\
Ceftriaxone620/mm^3^2Male69NoneFever\
Dry cough\
Dyspnea\
MyalgiasBilateral interstitial pneumonia43Hydroxychloroquine\
Lopinavir/ritonavir\
Amoxicillin/clavulanic acid820/mm^3^3Male79Parkinson disease\
MelanomaFever\
Skin rashNormal21None710/mm^3^[^1]Fig 1Patient 1: Vesicles and punched out perioral erosions.

Because the COVID-19 infection mechanism to produce vesicles is not known, we performed a herpesvirus family microarray polymerase chain reaction of the vesicle fluid, and we demonstrated a combination of herpes simplex-1 virus, herpes simplex-6 virus, and Epstein-Barr virus in patient 1, herpes simplex-1 virus and herpes simplex-7 in patient 2, and varicella zoster virus in patient 3. We could not simultaneously perform SARS-COV-2 polymerase chain reaction in the vesicle fluid, so we cannot completely rule out its additional involvement. Marzano and colleagues did not mention in their article whether they ruled out a herpes virus infection in every case; one might assume they did, and therefore used the term varicella-like exanthem.Fig 2Patient 3: Hemorrhagic blisters on the (**A**) anterior trunk and (**B**) posterior trunk.

COVID-19 infection characteristically produces lymphopenia, and we have previous evidence of lymphopenia, which is a known factor favoring herpesvirus recurrences, in our 3 patients. We would like to know whether the patients in the Marzano et al[@bib1] report also had this characteristic sign in their blood tests.

Finally, we agree with the idea of further studying this recently described varicella-like exanthem to clarify how we can distinguish it from other dermatosis and use it to identify otherwise asymptomatic patients to test them earlier. But even today, when it seems that all of our patients are affected by COVID-19 and all the skin diseases may be related to COVID-19, we must keep in mind that other dermatologic diseases still exist. That is why we think that when we face a patient presenting with a varicella-like rash, we should perform Tzanck smear, virus culture, polymerase chain reaction on the vesicle fluid, or skin biopsy, or a combination of these, to rule out disseminated forms of other common viral infections.
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[^1]: Lower count of lymphocytes of the patient during the follow-up of COVID-19 infection.
